AACR Annual Meeting | Conference

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC

April 10th 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Biomarker-Directed Therapy Could Lead to Undertreatment of Nonclonal Recurrent DCIS

April 10th 2022

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

April 10th 2022

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China

April 8th 2022

First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.

Temferon Displays Activity in Glioblastoma

April 8th 2022

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

cfMeDIP-seq Provides Opportunity for Early Cancer Detection, Classification, and Monitoring

May 18th 2021

Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

May 18th 2021

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Dr. Doroshow on the Importance of Modernizing Clinical Trials After COVID-19

May 18th 2021

James H. Doroshow, MD, discusses the importance of modernizing clinical trials in the post–COVID-19 era.

Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era

May 18th 2021

Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.

TIL-Based Therapies Possess Potential for Cure in Metastatic Melanoma, But Questions Remain

May 18th 2021

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers

May 17th 2021

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

Dr. Marron on the Population Included in a Phase 1 Study of PGV-001 Neoantigen Cancer Vaccine

May 13th 2021

Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.

Dr. Matasar on the Rationale for Combining Copanlisib and Rituximab in Indolent NHL

May 13th 2021

Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.

Dr. Le on Next Steps With Poziotinib in EGFR+ or HER2+ Exon 20 NSCLC

May 12th 2021

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

Dr. Hassan on the Mechanism of Action of Talazoparib in TNBC

May 12th 2021

Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.

Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts

April 15th 2021

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

Ahuno on Bringing Precision Medicine in Cancer Care to Ghana

April 14th 2021

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

Dr. Matasar on the Efficacy of Copanlisib Plus Rituximab in Indolent NHL

April 14th 2021

Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

Triplet Combos Targeting ER, CDK4/6, and PIK3CA Inhibit Tumor Growth in ER+ Breast Cancer

April 14th 2021

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

cfDNA Sequencing Shows Utility in Selecting KRAS G12C+ NSCLC for Sotorasib

April 14th 2021

Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.